Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose

Blood Cells, Molecules, and Diseases

Volumn 51, Issue 2, 2013, Pages 96-97

  Pongtanakul, Bunchoo ^a   Viprakasit, Vip ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; IRON;

ADULT; BLOOD TRANSFUSION; CLINICAL ARTICLE; COHORT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL IRRITATION; HUMAN; IRON OVERLOAD; KIDNEY FUNCTION TEST; LETTER; MALE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THALASSEMIA; URINALYSIS;

BENZOATES; BLOOD TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; THALASSEMIA; TREATMENT OUTCOME; TRIAZOLES;

EID: 84878403678     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.03.004     Document Type: Letter

References (8)

1. Cappellini M.D., Bejaoui M., Agaoglu L., Canatan D., Capra M., Cohen A., et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5years' follow-up. Blood 2011, 118:884-893.
2. Miyazawa K., Ohyashiki K., Urabe A., Hata T., Nakao S., Ozawa K., et al. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. Int. J. Hematol. 2008, 88:73-81.
3. Viprakasit V., Ibrahim H., Ha S.Y., Ho P.J., Li C.K., Chan L.L., et al. Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. Int. J. Hematol. 2011, 93:319-328.
4. Chang H.H., Lu M.Y., Liao Y.M., Lin P.C., Yang Y.L., Lin D.T., et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. Pediatr. Blood Cancer 2011, 56:420-424.
5. Chirnomas D., Smith A.L., Braunstein J., Finkelstein Y., Pereira L., Bergmann A.K., et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009, 114:4009-4013.
6. Otto-Duessel M., Aguilar M., Nick H., Moats R., Wood J.C. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp. Hematol. 2007, 2007(35):1069-1073.
7. Lu M.Y., Kuo P.H., Chiang P.H., W.H.W-HW, CY S., Lin K.H., et al. Therapeutic drug monitoring on twice-daily vs once-daily deferasirox dosing in thalassemia major patients. The 3rd Asia Pacific Iron Academy Conference (APIA); Exchanging expertise in iron science and research; 2012 November, 3-4, 2012 2012, 43. APIA & Taiwan Society of Blood and Marrow Transplantation, The Grand Hotel, Taipei, Taiwan. M.Y. Lu, K.H. Lin (Eds.).
8. Brewer C., Otto-Duessel M., Lykkesfeldt J., Nick H., Wood J.C. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats. Exp. Hematol. 2012, 40:820-827.